ALLO – Allogene Therapeutics, Inc.
Float Short %
16.09
Margin Of Safety %
Put/Call OI Ratio
0.48
EPS Next Q Diff
0.02
EPS Last/This Y
0.3
EPS This/Next Y
0.04
Price
1.2
Target Price
7.56
Analyst Recom
1.5
Performance Q
9.17
Relative Volume
1.91
Beta
0.37
Ticker: ALLO
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-25 | ALLO | 1.495 | 0.17 | 0.00 | 10308 |
| 2025-07-28 | ALLO | 1.465 | 0.17 | 0.01 | 10302 |
| 2025-07-29 | ALLO | 1.405 | 0.16 | 0.34 | 10467 |
| 2025-07-30 | ALLO | 1.29 | 0.17 | 0.78 | 10469 |
| 2025-07-31 | ALLO | 1.235 | 0.18 | 2.75 | 10702 |
| 2025-08-01 | ALLO | 1.085 | 0.20 | 6.22 | 10864 |
| 2025-08-04 | ALLO | 1.1 | 0.28 | 0.06 | 11712 |
| 2025-08-05 | ALLO | 1.115 | 0.28 | 0.00 | 11717 |
| 2025-08-06 | ALLO | 1.065 | 0.29 | 0.84 | 11709 |
| 2025-08-07 | ALLO | 1.055 | 0.29 | 1.15 | 11747 |
| 2025-08-08 | ALLO | 1.035 | 0.28 | 1.96 | 11662 |
| 2025-08-11 | ALLO | 1.035 | 0.28 | 2.81 | 11690 |
| 2025-08-12 | ALLO | 1.025 | 0.29 | 1.91 | 11753 |
| 2025-08-13 | ALLO | 1.045 | 0.29 | 4.52 | 11780 |
| 2025-08-14 | ALLO | 1.07 | 0.31 | 0.95 | 12082 |
| 2025-08-15 | ALLO | 1.105 | 0.30 | 1.72 | 12108 |
| 2025-08-18 | ALLO | 1.085 | 0.35 | 0.44 | 2914 |
| 2025-08-19 | ALLO | 1.045 | 0.35 | 0.63 | 3083 |
| 2025-08-20 | ALLO | 1.055 | 0.38 | 1.13 | 3627 |
| 2025-08-21 | ALLO | 1.125 | 0.40 | 4.46 | 3641 |
| 2025-08-22 | ALLO | 1.195 | 0.48 | 1.88 | 3916 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-25 | ALLO | 1.50 | 18.6 | - | -1.01 |
| 2025-07-28 | ALLO | 1.46 | 18.1 | - | -1.01 |
| 2025-07-29 | ALLO | 1.40 | 18.1 | - | -1.01 |
| 2025-07-30 | ALLO | 1.29 | 18.1 | - | -1.01 |
| 2025-07-31 | ALLO | 1.23 | 18.1 | - | -1.01 |
| 2025-08-01 | ALLO | 1.08 | 18.1 | - | -1.01 |
| 2025-08-04 | ALLO | 1.10 | 18.1 | - | -1.01 |
| 2025-08-05 | ALLO | 1.12 | 18.1 | - | -1.01 |
| 2025-08-06 | ALLO | 1.06 | 18.1 | - | -1.01 |
| 2025-08-07 | ALLO | 1.05 | 18.1 | - | -1.01 |
| 2025-08-08 | ALLO | 1.04 | 18.1 | - | -1.01 |
| 2025-08-11 | ALLO | 1.03 | 18.1 | - | -1.01 |
| 2025-08-12 | ALLO | 1.02 | 18.1 | - | -1.01 |
| 2025-08-13 | ALLO | 1.04 | 18.1 | - | -1.01 |
| 2025-08-14 | ALLO | 1.07 | 18.1 | - | -1.01 |
| 2025-08-15 | ALLO | 1.10 | 18.1 | - | -1.06 |
| 2025-08-18 | ALLO | 1.09 | 7.3 | - | -1.03 |
| 2025-08-19 | ALLO | 1.05 | 13.4 | - | -1.03 |
| 2025-08-20 | ALLO | 1.05 | 13.4 | - | -1.03 |
| 2025-08-21 | ALLO | 1.13 | 13.4 | - | -1.03 |
| 2025-08-22 | ALLO | 1.20 | 12.9 | - | -1.02 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-25 | ALLO | -0.29 | 5.82 | 17.34 |
| 2025-07-28 | ALLO | -0.29 | 4.34 | 17.34 |
| 2025-07-29 | ALLO | -0.29 | 4.34 | 17.34 |
| 2025-07-30 | ALLO | -0.29 | 4.34 | 17.34 |
| 2025-07-31 | ALLO | -0.29 | 4.34 | 17.34 |
| 2025-08-01 | ALLO | -0.29 | 4.34 | 17.34 |
| 2025-08-04 | ALLO | -0.29 | 1.53 | 17.34 |
| 2025-08-05 | ALLO | -0.29 | 1.53 | 17.34 |
| 2025-08-06 | ALLO | -0.16 | 1.53 | 17.34 |
| 2025-08-07 | ALLO | -0.16 | 1.53 | 17.34 |
| 2025-08-08 | ALLO | -0.16 | 1.53 | 17.34 |
| 2025-08-11 | ALLO | -0.16 | 1.29 | 17.34 |
| 2025-08-12 | ALLO | -0.16 | 1.29 | 16.36 |
| 2025-08-13 | ALLO | -0.16 | 1.29 | 16.36 |
| 2025-08-14 | ALLO | -0.16 | 1.29 | 16.36 |
| 2025-08-15 | ALLO | -0.16 | 1.29 | 16.32 |
| 2025-08-18 | ALLO | -0.16 | -2.02 | 16.09 |
| 2025-08-19 | ALLO | -0.16 | -2.02 | 16.09 |
| 2025-08-20 | ALLO | -0.16 | -2.02 | 16.09 |
| 2025-08-21 | ALLO | -0.14 | -2.02 | 16.09 |
| 2025-08-22 | ALLO | -0.14 | -2.02 | 16.09 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.23
Avg. EPS Est. Current Quarter
-0.23
Avg. EPS Est. Next Quarter
-0.21
Insider Transactions
-0.14
Institutional Transactions
-2.02
Beta
0.37
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
9
Growth Score
22
Sentiment Score
80
Actual DrawDown %
97.3
Max Drawdown 5-Year %
-97.8
Target Price
7.56
P/E
Forward P/E
PEG
P/S
P/B
0.76
P/Free Cash Flow
EPS
-1.11
Average EPS Est. Cur. Y
-1.02
EPS Next Y. (Est.)
-0.98
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
1.91
Return on Equity vs Sector %
-93.4
Return on Equity vs Industry %
-80.5
EPS 1 7Days Diff
EPS 1 30Days Diff
0.01
EBIT Estimation
Allogene Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 226
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
stock quote shares ALLO – Allogene Therapeutics, Inc. Stock Price stock today
news today ALLO – Allogene Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALLO – Allogene Therapeutics, Inc. yahoo finance google finance
stock history ALLO – Allogene Therapeutics, Inc. invest stock market
stock prices ALLO premarket after hours
ticker ALLO fair value insiders trading